#AAD2019

Highlights AEDV

In 77TH AAD Congress

1-5 March 2019

★ Washington ★

Scientific Initiative of:

Sponsored by:

NOVARTIS

#AAD2019

Highlights AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Oncology and surgery: Skin Cancer I Melanoma

Dr. David Moreno Ramírez

Scientific Initiative of:

Sponsored by:

NOVARTIS

SKIN CANCER I. MALIGNANT MELANOMA

Friday sessions on malignant melanoma:

- U011 - Paradigm Shift in the Management of High Risk Melanoma
- S001 - Melanoma: The Future is Now
- S017 - Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines

MELANOMA: THE FUTURE IS NOW



- **Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.**

Gastman et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

FROM THE ACADEMY

Guidelines of care for the management of primary cutaneous melanoma

Work Group: Susan M. Swetter, MD (Chair),[a,b] Hensin Tsao, MD, PhD (Co-Chair),[c,d] Christopher K. Bichakjian, MD,[e,f] Clara Curiel-Lewandrowski, MD,[g,h] David E. Elder, MBChB,[i,j] Jeffrey E. Gershenwald, MD,[k,l] Valerie Guild, MS, MBA,[m] Jane M. Grant-Kels, MD,[n,o,p] Allan C. Halpern, MD,[q] Timothy M. Johnson, MD,[e,f] Arthur J. Sober, MD,[c] John A. Thompson, MD,[r,s] Oliver J. Wisco, DO,[t] Samantha Wyatt, MD,[u] Shasa Hu, MD,[v] and Toyin Lamina, PhD[w]

Stanford and Palo Alto, California; Boston, Massachusetts; Ann Arbor, Michigan; Tucson, Arizona; Philadelphia, Pennsylvania; Houston and Plano, Texas; Farmington, Connecticut; New York, New York; Seattle, Washington; Portland, Oregon; Decatur, Alabama; Miami, Florida; and Rosemont, Illinois

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

- Genetic Expression Profile Testing:
- There is insufficient evidence to recommend routine molecular profiling assessment for baseline prognostication
- Evidence is lacking that molecular classification should be used to alter patient management outside of current guidelines (NCCN and AAD)
- The utility of prognostic molecular testing, including GEP, in aiding clinical decision making needs to be evaluated in the context of clinical study or trial

Guidelines of care for the management of primary cutaneous melanoma
Swetter et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

Primary Surgery & Mohs Surgery for Lentigo Maligna

Dr. Durham, Dr. Wisco

- Surgical margins for invasive CM should be 1-2cm
- Melanoma in situ: 0.5-1.0cm margins
- Lentigo Maligna type, may require >0.5cm
- **Mohs micrographic surgery or staged excision:**
  - Lentigo Maligna on the face, ears, or scalp
  - Permanent section of the central MMS debulking
  - **If invasive CM is identified submit for formal pathology review**

Guidelines of care for the management of primary cutaneous melanoma
Swetter et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

Alternative Therapies for Lentigo Maligna

Dr. Nelson

- Topical imiquimod 5%:
  - Primary therapeutic intent: when surgery is not posible
  - Adjuvant therapeutic intent: after optimal surgery
  - Neoadjuvant intent

- Radiotherapy:
  - When surgery is not posible (uncommon in the USA)
  - Superficial brachytherapy is not recommended.

Guidelines of care for the management of primary cutaneous melanoma
Swetter et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

Workup & Follow-up

Dr. Swetter

Recommendations for baseline and surveillance studies and follow-up

- **Basal imaging and laboratory not recommended** for asymptomatic patients with stage 0-II
- **Ultrasound** is encouraged if:
  - Equivocal LN on physical examination, and for surveillance when:
  - SLNB not performed (meeting criteria), not posible or not technically successful
  - CLND is not performed in the setting (with +SLNB)
- **Laboratory not recommended for surveillance** of asymptomatic patients

Guidelines of care for the management of primary cutaneous melanoma
Swetter et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

Sentinel lymph node biopsy

Dr. Curiel-Lewandrowsky

"SLNB staging accuracy is not controversial"

Recommendations for SLNB:

- **Stage T1b:**
  - <0.8mm with ulceration
  - 0.8-1.0mm with or without ulceration
- **Stage T1a:** young age, presence of lymphovascular invasion, positive deep biopsy margin (if close to 0.8 mm), high mitotic rate, or a combination of these factors.

Guidelines of care for the management of primary cutaneous melanoma
Swetter et al. J Am Acad Dermatol 2019

TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES

Newer adjuvant therapies for metastasic melanoma

Dr. Tsao